Projects per year
Personal profile
Biography
Ian Glaspole performs translational and clinical research in interstitial lung diseases, such as idiopathic pulmonary fibrosis. He is the director of the Interstitial Lung Disease Clinic at the Alfred Hospital, Melbourne. He is an adjunct clinical associate professor of medicine at Monash University’s School of Translational Medicine.
A/Prof Glaspole has maintained a strong research focus since completing his PhD, within which he studied the human cellular immune response to nut allergens. Since then, his research has focused on interstitial lung disease, and has included numerous clinical trials exploring treatments for idiopathic pulmonary fibrosis, along with other clinical and laboratory based research, principally focused on improving the symptoms and quality of life of sufferers of these rare lung diseases.
His research is funded by the NHMRC, and philanthropic and industry sources. He serves on advisory boards and steering committees for clinical trials in idiopathic pulmonary fibrosis (IPF) and other forms of lung fibrosis. He is the co-chair of the Australian IPF Registry, and a steering committee member of the Centre for Research Excellence in Pulmonary Fibrosis.
A/Prof Glaspole is a member of the Thoracic Society of Australia & New Zealand, the Australian Society of Clinical Immunology and Allergy, and the Australian Sleep Association.
Research area keywords
- Interstitial lung disease
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
-
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof of Concept (POC) Study Evaluating the Safety, Tolerability, and Efficacy of Nintedanib Solution for Inhalation (AP02) in Participants with Idiopathic Pulmonary Fibrosis (IPF) (AURA-IPF)
Glaspole, I. (Chief Investigator (CI))
16/07/26 → 15/07/28
Project: Research
-
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791in Subjects with Idiopathic Pulmonary Fibrosis
Glaspole, I. (Primary Chief Investigator (PCI))
11/05/26 → 10/05/28
Project: Research
-
A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis to reduce the risk of worsening (DROP-FPF)
Glaspole, I. (Primary Chief Investigator (PCI))
27/04/26 → 1/12/30
Project: Research
-
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Glaspole, I. (Primary Chief Investigator (PCI))
29/09/25 → 30/04/28
Project: Research
-
A randomised, double-blind, placebo-controlled, dosefinding study evaluating efficacy, safety and tolerability of different oral doses of BI1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF)
Glaspole, I. (Primary Chief Investigator (PCI))
25/09/24 → 25/09/26
Project: Research
-
Usability of a smartphone application for patients with interstitial lung disease: Results from the Registry for Better Understanding of ILD (RE-BUILD) pilot study
Glenn, L. M., Jackson, D., Barton, C., Lan, D., Fuhrmeister, L., Symons, K., Turnour, L., Tefay, B., Holland, A. E., Goh, N. S. L., Troy, L. K., Brooke, M., Glaspole, I. N. & Corte, T. J., Feb 2025, In: Respirology. 30, 2, p. 147-157 11 p.Research output: Contribution to journal › Article › Research › peer-review
7 Link opens in a new tab Citations (Scopus) -
A self-management package for pulmonary fibrosis: A feasibility study
Lee, J. Y. T., Tikellis, G., Hoffman, M., Mellerick, C. R., Symons, K., Bondarenko, J., Khor, Y. H., Glaspole, I. & Holland, A. E., 15 Dec 2024, In: PEC Innovation. 5, 8 p., 100328.Research output: Contribution to journal › Article › Research › peer-review
Open Access6 Link opens in a new tab Citations (Scopus) -
Exertional Desaturation During the 6-Minute Walk Test vs Daily Life in People With Fibrotic Interstitial Lung Disease
Hoffman, M., Burge, A. T., Wong, N., McDonald, C. F., Chambers, D. C., Glaspole, I., Mackintosh, J. A., Ekström, M., Sköld, M., Goh, N. S. L., Corte, T. J. & Holland, A. E., Mar 2024, In: Chest. 165, 3, p. 632-635 4 p.Research output: Contribution to journal › Letter › Research › peer-review
Open Access9 Link opens in a new tab Citations (Scopus) -
Implications of the 2022 lung function update and GLI global reference equations among patients with interstitial lung disease
Li, A., Teoh, A., Troy, L., Glaspole, I., Wilsher, M. L., de Boer, S., Wrobel, J., Moodley, Y. P., Thien, F., Gallagher, H., Galbraith, M., Chambers, D. C., Mackintosh, J., Goh, N., Khor, Y. H., Edwards, A., Royals, K., Grainge, C., Kwan, B. & Keir, G. J. & 9 others, , Nov 2024, In: Thorax. 79, 11, p. 1024-1032 9 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access10 Link opens in a new tab Citations (Scopus) -
Navigating the COVID-19 pandemic: Experiences and self-management approaches adopted by people with interstitial lung disease
Tikellis, G., Corte, T., Glaspole, I. N., Goh, N. S. L., Khor, Y. H., Wrobel, J., Symons, K., Fuhrmeister, L., Glenn, L., Chirayath, S., Troy, L. K., King, B. & Holland, A. E., 2024, In: Chronic Respiratory Disease. 21, p. 1-10 10 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access5 Link opens in a new tab Citations (Scopus)